Levetiracetam in chronic daily headache: A double-blind, randomised placebo-controlled study: (The Australian KEPPRA Headache Trial [AUS-KHT])

Cephalalgia

Volumn 31, Issue 5, 2011, Pages 530-536

  Beran, Roy G ^a   Spira, Paul J ^b  

^a GRIFFITH UNIVERSITY   (Australia)

^b PRINCE OF WALES HOSPITAL   (Australia)

Author keywords

chronic daily headache; levetiracetam; Placebo controlled; treatment

Indexed keywords

ETIRACETAM; PLACEBO;

ADULT; AGED; ARTICLE; CHRONIC DAILY HEADACHE; CLINICAL FEATURE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISABILITY; DISEASE DURATION; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; FEMALE; HEMIPLEGIC MIGRAINE; HUMAN; LETHARGY; MAJOR CLINICAL STUDY; MALE; MIGRAINE WITH AURA; MIGRAINE WITHOUT AURA; MULTICENTER STUDY; PAIN ASSESSMENT; PHASE 3 CLINICAL TRIAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SHORT FORM 36; TENSION HEADACHE; TREATMENT DURATION; VISUAL ANALOG SCALE;

ADOLESCENT; ADULT; AGED; ANALGESICS; AUSTRALIA; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; HEADACHE DISORDERS; HUMANS; MIDDLE AGED; PAIN MEASUREMENT; PIRACETAM; QUALITY OF LIFE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79953174290     PISSN: 03331024     EISSN: 14682982     Source Type: Journal    
DOI: 10.1177/0333102410384886     Document Type: Article

References (32)

1. Sjaastad O. Chronic daily headache. Cephalalgia 1985 ; 5 (Suppl 2): 19-193.
2. Silberstein SD, Lipton RB and Sliwinski M. Classification of daily and near-daily headaches: field trial of revised HIS criteria. Neurology 1996 ; 47: 871-875.
3. Solomon S., Lipton RB and Newman LC Evaluation of chronic daily headache-comparison to criteria for chronic tension-type headache. Cephalalgia 1992 ; 12: 365-368. (Pubitemid 23003730)
4. Mathew NT, Reuveni U. and Perez F. Transformed or evolutive migraine. Headache 1987 ; 27: 102-106. (Pubitemid 17152607)
5. Sanin LC, Mathew N., Belmeyer LR and Ali S. The International Headache Society (IHS) classification as applied to a headache clinic population. Cephalalgia 1994 ; 14: 443-446. (Pubitemid 24381759)
6. Martens-Lobenhoffer J. and Bode- Boger S. Determination of levetiracetam in human plasma with minimal sample pre-treatment. J Chromatogr B 2005 ; 1: 197-200. (Pubitemid 41583181)
7. Patsalos P. Clinical pharmacokinetics of levetiracetam. Clin Pharmacokinet 2004 ; 11: 707-724. (Pubitemid 39159001)
8. Shorvon SD and van Rijckervorsel K. A new anti-epileptic drug. J Neurol Neurosurgery Psychiatry 2002 ; 72: 426-429.
9. Gower A., Noyer M., Verloes R., Gobert J. and Wulferte E. ucb L059, a novel anti-convulsant drug: pharmacological profile in animals. Eur J Pharmacol 1992 ; 27: 193-203.
10. Ardid D., Lamberty Y., Alloui A., Coudore-Civiale M., Klitgaard H. and Eschalier A. Anti-hyperalgesic effect of levetiracetam in neuropathic pain models in rats. Eur J Pharmacol 2003 ; 473: 27-33. (Pubitemid 36851625)
11. Archer D., Lamberty Y., Wang B., Davis M., Sumanani N. and Roth S. Levetiracetam reduces anaesthetic induced hyperalgesia in rats. Anesth Analg 2007 ; 104: 180-185. (Pubitemid 46360444)
12. Lamberty Y., Margineanu D. and Klitgaard H. Effect of the new anti-epileptic drug levetiracetam in an animal model of mania. Epilepsy Behaviour 2001 ; 2: 454-459. (Pubitemid 33585802)
13. Mathew NT and Ali S. Valproate in the treatment of persistent chronic daily headache. an open label study. Headache 1991 ; 13: 71-74.
14. Vijayan N. and Spillane T. Valproic acid treatment of chronic daily headache. Headache 1995 ; 35: 540-543.
15. Spira PJ and Beran RG Gabapentin in the prophylaxis of chronic daily headache: a randomised, placebo-controlled study. Neurology 2003 ; 61: 1753-1759. (Pubitemid 38020824)
16. Diener HC, Tfelt-Hansen P., Dahlöf C., et al. Topiramate in migraine prophylaxis-results from a placebo-controlled trial with propranolol as an active control. J Neurol 2004 ; 251 (8). 943-950. (Pubitemid 39119312)
17. Silberstein SD, Lipton RB, Dodick DW, et al. on behalf of the Topiramate Chronic Migraine Study Group. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache 2007 ; 47: 170-180.
18. Headache Classification Committee of the International Headache Society. The international classification of headache disorders. 2 nd ed. Cephalalgia 2004 ; 24 (Suppl 1): 9-160.
19. Frediani F. Anticonvulsant drugs in primary headache prophylaxis. Neurol Sci 2004 ; 25 (Suppl 3): S161 - S166.
20. Bigal ME, Krymchantowski AV and Rapoport AM Prophylactic migraine therapy: emerging treatment options. Curr Pain Headache Rep 2004 ; 9 (3). 178-184. (Pubitemid 38915103)
21. Miller GS and Steve MD Efficacy and safety of levetiracetam in paediatric migraine. Headache 2004 ; 44 (3). 238-243. (Pubitemid 38436686)
22. Pakalnis A., Kruig D. and Meier L. Levetiracetam prophylaxis in paediatric migraine: an open label study. Headache 2007 ; 47 (3). 427-430. (Pubitemid 46426416)
23. Gallai V., Alberti A., Rossi C., et al. An open label pilot study on the efficacy and tolerability of levetiracetam in the prophylaxis of migraine. J Headache Pain 2003 ; 4: 92-96. (Pubitemid 37062824)
24. Brighina F., Palermo A., Aloisio A., Francolini M., Gigliag G. and Fierro B. Levetiracetam in the prophylaxis of migraine with aura: a 6-month open-label study. Clin Neuropharmacol 2006 ; 29 (6). 338-342. (Pubitemid 44729945)
25. Rapoport AM, Sheftell FD, Tepper SJ and Bigal ME Levetiracetam in the preventative treatment of transformed migraine: a prospective open-label, pilot study. Curr Ther Res 2005 ; 66 (3). 212-221. (Pubitemid 41673304)
26. Young W., Shaw J., Bloom M. and Gebelina-Myers BS Correlation of increase in phosphene threshold with reduction of migraine frequency: observation of levetiracetam treated subjects. Headache 2008 ; 48: 1490-1498.
27. Kramer J., de Rue K., Devinsky O., Edrich P. and Trimble M. A systemic review of the behavioural effects of levetiracetam in adults with epilepsy, cognitive disorders, or an anxiety disorder during clinical trials. Epilepsy Behaviour 2003 ; 4: 124-132. (Pubitemid 37184583)
28. White JR, Walczak TS, Leppik IE, et al. Discontinuation of levetiracetam because of behavioural side effects. Neurology 2003 ; 61: 1218-1221. (Pubitemid 37377540)
29. Moerman DE and Jonas WB Deconstructing the placebo effect and finding the meaning response. Intern Med 2002 ; 13: 471-476. (Pubitemid 34233178)
30. Diener HC, Schorn CF, Bingel U. and Dodick DW Importance of placebo in headache research. Cephalalgia 2008 ; 28: 1003-1011.
31. Antonaci F., Chimento P., Diener HC, Sances G. and Bono G. Lessons from placebo effects in migraine treatment. J Headache Pain 2007 ; 8: 63-66. (Pubitemid 46443516)
32. Reuter U., Sanchez del Rio M., Carpay JA, Boes CJ and Silberstein SD Placebo adverse events in headache trials: headache as an adverse event of placebo. Cephalalgia 2003 ; 23: 496-503. (Pubitemid 37114970)